ImmunoGen, Inc. Profile Avatar - Palmy Investing

ImmunoGen, Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]

News

Theses · Events · Sentiments
End of IMGN's Analysis
CIK: 855654 CUSIP: 45253H101 ISIN: US45253H1014 LEI: - UEI: -
Secondary Listings